Pharmacology of acute lung injury

Pulmonary Pharmacology and Therapeutics

Volumn 15, Issue 2, 2002, Pages 83-95

  Tasaka, Sadatomo ^a,b,c   Hasegawa, Naoki ^a   Ishizaka, Akitoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON KOKAN HOSPITAL   (Japan)

^c TOKYO ELECTRIC POWER COMPANY   (Japan)

Author keywords

ALI ARDS; Pharmacological treatment; Sepsis

Indexed keywords

AFELIMOMAB; ALMITRINE; ANTITHROMBIN III; CD18 ANTIGEN; CORTICOSTEROID; GLUCOCORTICOID; HYDRALAZINE; INTERLEUKIN 6; KETOCONAZOLE; KL4 SURFACTANT; LEUKOCYTE ELASTASE INHIBITOR; LISOFYLLINE; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; MATRIX PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD18; NEUTRALIZING ANTIBODY; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PENTOXIFYLLINE; PROSTACYCLIN; PROSTAGLANDIN E1; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANTICOAGULATION; APOPTOSIS; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE COURSE; DRUG SCREENING; FLUID THERAPY; HIGH RISK POPULATION; HUMAN; LUNG INJURY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SURGICAL PATIENT; SURVIVAL;

EID: 0036318639     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2001.0325     Document Type: Review

References (150)

1. Acute respiratory distress in adults
2. The adult respiratory distress syndrome: Clinical features, factors influencing prognosis and principles of management
3. An expanded definition of the adult respiratory distress syndrome
4. The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial condition
5. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993
6. Reduced mortality in association with the acute respiratory distress syndrome (ARDS)
7. High inflation pressure pulmonary edema: Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure
8. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome
9. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk of acute respiratory distress syndrome
10. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome
11. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome
12. Multiple system organ failure. Is mechanical ventilation a contributing factor?
13. The incidence of the adult respiratory distress syndrome
14. Incidence of the adult respiratory distress syndrome in the State of Utah
15. Incidence, severity, and mortality of acute respiratory failure in Berlin, Germany
16. Epidemiology of acute lung injury and ARDS
17. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark and Iceland
18. Clinical risks for development of the acute respiratory distress syndrome
19. Acute lung injury in the medical ICU
20. Identification of patients with acute lung injury
21. Causes of mortality in patients with the adult respiratory distress syndrome
22. Is outcome from ARDS related to the severity of respiratory failure?
23. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993
24. Reduced mortality in association with the acute respiratory distress syndrome (ARDS)
25. Lung structure and function in different stages of severe adult respiratory distress syndrome
26. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids
27. Influence of direct and indirect etiology on acute outcome and 6-month functional recovery in acute respiratory distress syndrome
28. Clinical trials of mediator-directed therapy in sepsis: What have we learned?
29. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
30. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial
31. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized double-blind, placebo-controlled trial
32. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
33. CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
34. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial
35. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis
36. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
37. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
38. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
39. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
40. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
41. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial
42. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
43. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock
44. Impact of immunomodulating therapy on morbidity in patients with severe sepsis
45. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
46. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial
47. Inhibition of CD18-dependent neutrophil adherence reduces organ injury after hemorrhagic shock in primates
48. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits
49. Pilot phase 2 clinical trial of a humanized CD11/CD18 monoclonal antibody in hemorrhagic shock
50. Inhaled nitric oxide: A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction
51. Inhaled nitric oxide for the adult respiratory distress syndrome
52. Effectiveness of nitric oxide inhalation in septic ARDS
53. Inhaled nitric oxide in acute respiratory distress syndrome: A pilot randomized controlled study
54. Effects of inhaled nitric oxide for the acute respiratory distress syndrome: Results of a randomized phase II trial
55. Results of French prospective multicentric randomized double-blind placebo-controlled trial on inhaled nitric oxide in ARDS
56. Inhalation of nitric oxide in acute lung injury: Results of a European multicentre study
57. Efficacy of inhaled nitric oxide in patients with severe ARDS
58. Nitric oxide reduces the sequestration of polymorphonuclear leukocytes in lung by changing deformability and CD18 expression
59. Inhaled NO prevents IL-1-induced neutrophil accumulation and associated acute edema in isolated rat lungs
60. A new side effect of inhaled nitric oxide in neonates and infants with pulmonary hypertension: Functional impairment of the neutrophil respiratory burst
61. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury
62. Inhaled nitric oxide modulates leukocyte kinetics in the mesenteric venules of endotoxemic rats
63. The toxicology of inhaled nitric oxide
64. Surfactant therapy in acute respiratory distress syndrome
65. Evidence of lung surfactant abnormality in respiratory failure: Study of bronchoalveolar lavage phospholipids, surface activity, and plasma myoinositol
66. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock
67. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
68. Effect of exogenous surfactant instillation on experimental acute lung injury
69. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome
70. Aerosolized surfactants in adults with sepsis-induced acute respiratory distress syndrome
71. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties
72. Bovine surfactant therapy for patients with acute respiratory distress syndrome
73. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome
74. Surfactant lavage treatment in a model of respiratory distress syndrome
75. Bronchopulmonary segmental lavage with Surfaxin (KL4-surfactant) for acute respiratory distress syndrome
76. ARDS neutrophils, and pentoxifylline
77. Attenuation of acute lung injury in septic guinea pigs by pentoxifylline
78. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome
79. The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs
80. Lisofylline versus placebo for ALI and ARDS
81. Ketoconazole prevents acute respiratory failure in critically ill surgical patients
82. A double-blind, prospective, randomized trial for ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome
83. Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome)
84. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome
85. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial
86. Randomized double-blinded, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome
87. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: A controlled, randomized, double-blind, multicenter clinical trial
88. Effect of sodium nitroprusside on cardiovascular function and pulmonary shunt in canine oleic acid pulmonary edema
89. Hydralazine does not inhibit canine hypoxic pulmonary vasoconstriction
90. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: Effects on pulmonary capillary pressure and ventilation-perfusion distributions
91. Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome
92. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome
93. Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome
94. High-dose corticosteroids in patients with the adult respiratory distress syndrome
95. Early methylprednisolone treatment for septic syndrome and the adult respiratory syndrome
96. Ine3ectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock
97. Effects of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial
98. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure
99. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization
100. Fluid balance during pulmonary edema. Is fluid gain a marker or a cause of poor outcome?
101. Role of the coagulation system in ARDS
102. Coagulation abnormalities in acute lung injury and sepsis
103. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons
104. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
105. Blood-borne tissue factor: Another view of thrombosis
106. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
107. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
108. Therapeutic use of antithrombin concentrate in sepsis
109. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
110. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
111. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies
112. Efficacy and safety of recombinant human activated protein C for severe sepsis
113. Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory distress syndrome
114. Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury
115. Effects of a neutrophil elastase inhibitor (ONO-5046) on acute pulmonary injury induced by tumor necrosis factor alpha (TNFalpha) and activated neutrophils in isolated perfused rabbit lungs
116. Efficacy of intravenous ICI 200,880, a neutrophil elastase inhibitor, in the treatment of adult respiratory distress syndrome
117. Low-molecular synthetic neutrophil elastase inhibitor can prevent/improve lung injury caused by various complications
118. Shrinkage necrosis: A distinct mode of cellular death
119. Mechanisms and genes of cellular suicide
120. Apoptosis in resolution of inflammation
121. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators
122. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome
123. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation
124. Nitric oxide inhibits lipopolysaccharide-induced apoptosis in pulmonary artery endothelial cells
125. Cytokine signaling-regulation of the immune response in normal and critically ill states
126. Regulation of immune responses by NF-κB/Rel transcription factors
127. Signal transduction through NK-κB
128. In vivo antioxidant treatment suppresses nuclear factor-kB activation and neutrophilic lung inflammation
129. Systemic blood loss affects NF-κB regulatory mechanisms in the lungs
130. Hyperoxia activates NF-κB and increases TNF-α and INF-γ; gene expression in mouse pulmonary lymphocytes
131. Mechanisms of lung neutrophil activation after hemorrhage or endotoxemia: Roles of reactive oxygen intermediates, NF-κB, and CREB
132. NF-κB is activated in alveolar macrophages from patients with acute respiratory distress syndrome
133. The dorsoventral regulatory gene cassetted Spaetzle/Toll/cactus controls the potent antifungal response in Drosophila adults
134. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
135. A family of human receptors structurally related to Drosophila toll
136. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene
137. TLR4-deficient mice are hyporesponsive to LPS: Evidence for TLR4 as the Lps gene product
138. Differential roles of Toll-like receptor (TLR)2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components
139. Role of matrix metalloproteinases in normal and disease processes
140. Tissue inhibitors of metalloproteinases: Evolution, structure and function
141. Matrix metalloproteinase and TIMP in acute respiratory distress syndrome
142. Gelatinases in epithelial lining fluid of patients with adult respiratory distress syndrome
143. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome
144. Role of gelatinase MMP-2 and MMP-9 in tissue remodeling following acute lung injury
145. Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor
146. Gene therapy for acute lung injury
147. Protection of rabbit lungs from endotoxin injury by in vivo hyperexpression of the prostaglandin G/H synthase gene
148. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury
149. Transient gene transfer and expression of Smad 7 prevents bleomycin-induced lung fibrosis in mice